troke is an acute temporary, or often permanent damage of the brain. In industrialized countries stroke is the third leading cause of death after cardiovascular disorders and malignant tumors. 1 It can affect both sexes at any time of life; however, it is more prevalent in males and people over 50 years of age. Ischemic stroke results in local dysfunction of the brain and comprises 80% of cases. 2 Ischemic stroke can be unequivocally attributed to numerous classic clinical and environmental risk factors, such as diabetes mellitus, hypertension, smoking and excessive alcohol or drug consumption. 3 The role of several factors in the development of the disease is still the subject of investigations, including the possible significance of increased triglyceride levels. In the past decade numerous genetic susceptibility factors have been verified, which alone or in combination with other genes or exogenous factors can have a role in the development of stroke. [4] [5] [6] [7] The apolipoprotein A5 (APOA5) gene is located nearby the APOAI-APOCIII-APOAIV cluster in the 11q23 chro-
176 patients (67 males, 109 females; mean age: 66.6±1.17 years, range: 36-94) with small-vessel infarcts (1 or more subcortical hemispheric or brainstem infarcts with a diameter <1.5 cm on MRI, with 1 of the features of the traditional clinical lacunar syndrome and without cerebral cortical dysfunction); 122 patients (50 males, 72 females; mean age: 67.6±1.30 years, range: 24-95) comprised the large-vessel group, having cortical or cerebellar lesions and/or brainstem infarcts or subcortical hemispheric infarcts greater than 1.5 cm in diameter on MRI, with or without cerebral cortical impairment or brainstem or cerebellar dysfunction; the third cohort, the mixed group, comprised 80 patients (33 males, 47 females; mean age: 63.0±1.35 years, range: 30-83) with 1 or more lacunar and large-vessel infarcts on MRI, and other non-specific etiology. A total of 131 Caucasian unrelated individuals (41 males, 90 females; mean age: 58.1± 1.51 years, range: 25-93) free from neuro-imaging alterations and clinical history of stroke events were enrolled as the control group. Other parameters, such as the high-density lipoprotein-cholesterol levels, of the subjects were not available for the study.
The DNA samples were deposited into the Biobank of our department, which belongs to the Central National Biobank Network of Hungary (www.biobank.hu). During the collection and use of DNA samples, the clinical data guidelines and regulations of the local ethics committee and of the Helsinki Declaration in 1975 were followed; at the time of blood collection patients gave informed consent for the future use of their anonymous DNA. 15 
Molecular Genetics
The molecular analyses were performed using DNA extracted from peripheral blood leukocytes with a routine salting out procedure. The T-1131C, T1259C and IVS3+
G476A variants of APOA5 were tested by restriction fragment length polymorphism after polymerase chain reaction (PCR) amplification. For PCR the following oligonucleotide primers were designed by GenBank reference sequence AY 422949; for T-1131C: 5' CCC CAG GAA CTG GAG CGA AAT T-3' and 5'-TTC AAG CAG AGG GAA GCC TGT A-3'; for T1259C: 5'-TCA GTC CTT GAA AGT GGC CT-3' and 5'-ATG TAG TGG CAC AGG CTT CC-3'; for IVS3+G476A: 5'-CTC AAG GCT GTC TTC AG-3' and 5'-CCT TTG ATT CTG GGG ACTG G-3'. The PCR conditions for the detection of T1259C and IVS3+G476A were as follows: initial denaturation at 96°C followed by 35 cycles of 30 s at 95°C; 30 s at 64°C; 30 s at 72°C and a final extension at 72°C. The annealing temperature for T-1131C was 55°C, but the other conditions of PCR were the same as described above. The amplifications were carried out in a final volume of 50 l containing 0.2 mmol/L of each dNTP, 0.2 mmol/L of each primer, 5 l of reaction buffer (containing 500 mmol/L KCl, 100 mmol/L Tris-HCl, 15 mmol/L MgCl2, pH 9.0), 1 U of Taq polymerase and 1 g extracted DNA.
Ten microlitres of PCR products were digested with 1 U of appropriate restriction endonuclease and electrophoresed through an ethidium-bromide-stained 3% agarose gel. The primers were designed to create obligatory cleavage sites of the proper restriction enzymes in the amplicons to control the accuracy of the digestion. The PCR amplification in the region of T-1131C resulted in a 398-bp product, which was digested with MseI restriction enzyme at 65°C. The forward primer contained a false T base (boldface letter) instead of G to create an artificial obligatory MseI recognition site (underlined). In the samples with a TT genotype the digestion resulted in 22-, 109-and 267-bp bands. In the samples carrying the mutation in heterozygous form (TC), 22-, 109-, 267-and 289-bp digestion products were detected. In the samples with a CC genotype, 109-and 289-bp products were formed. The 287-bp PCR product for T1259C was digested with BseGI at 55°C, which resulted in 122-and 165-bp fragments in the samples with TT genotype. In the heterozygous samples (TC), 35-, 87-, 122-and 165-bp products were detected. In the samples carrying the mutation in homozygous form (CC), 35-, 87-and 165-bp fragments were produced. The 280-bp amplified product in the region of IVS3+G476A was digested with MnlI at 37°C. The fragments were 25, 114 and 141 bp in the GG genotype. Heterozygous samples (GA) formed 25-, 41-, 73-, 114-and 141-bp fragments, whereas in specimens with the homozygous mutation (AA), there were 25-, 41-, 73-and 141-bp fragments.
Statistical Analysis
All clinical data are expressed as mean ± SEM. The distributions of the variables were examined using the Kolmogorov-Smirnov test. As all the variables did not show Gaussian distribution, we applied nonparametric tests. First, we checked for possible differences among all groups and subgroups using the Kruskal-Wallis test. To compare the differences between groups we used the Mann-Whitney Utest for continuous variables and the 2 test for discreet variables. Crude and adjusted odds ratios (OR) derived from multiple logistic regression analysis was carried out to evaluate the impact of the APOA5 genotype on the development of stroke at 95% confidence intervals. All statistical analyses were performed using SPSS 11.0 package for Windows (SPSS Inc, Chicago, IL, USA).
Results
The major clinical features and laboratory parameters of the patients and controls are summarized in Table 1 . The serum total cholesterol and triglyceride levels were elevated in all stroke groups compared with the controls.
The serum triglycerides and total cholesterol levels in each stroke type and in the controls with different genotypes are shown in Table 2 . The triglyceride levels were significantly elevated in subjects carrying the minor APOA5 alleles, compared with non-carriers in both all stroke patients and in the controls. The serum total cholesterol levels did not show allele specific difference in any groups. Table 3 shows the distribution of the T-1131C, T1259C, IVS3+G476A genotypes. The allele distributions of all 3 alterations were in Hardy-Weinberg equilibrium in the stroke subgroups and in the controls. The -1131C and IVS3+476A alleles were more frequent in all stroke subgroups compared with controls. By contrast, none of the 1259T or C allelic variants showed accumulation in any of the stroke types.
The results of multivariate regression assays are summarized in Table 4 . As shown, the -1131C and IVS3+476A alleles represent independent risk factors for all subtypes of ischemic stroke. In contrast, we could not detect any association between 1259C and the development of the stroke disease. After adjusting for differences in age, gender, body mass index, serum total cholesterol, ischemic heart disease, hypertension, diabetes mellitus, smoking-and drinking habits, the adjusted OR for -1131C and for IVS3+476A represented a 2-4-fold risk for the development of stroke. After inclusion of triglyceride levels into the adjustment criteria, we also found positive associations. Table 5 shows the distribution of some selected APOA5 haplotypes and the results of multivariate regression analyses in the stroke patients and in controls. An approximately 3-fold accumulation of the APOA5*2 haplotype could be seen in each stroke subgroup compared with the controls. The regression analysis revealed that carriage of the APOA5*2 haplotype confers risk for ischemic stroke. After inclusion of the adjustment parameters mentioned above the association came even stronger.
Discussion
The role of elevated triglyceride levels in the development of ischemic stroke has not been unequivocally delineated. 16, 17 The circulating triglyceride concentration is influenced by exogenous conditions such as nutrition, drinking and smoking habits, but differences in triglyceride levels can also be attributed to genetic factors. 18 Elevated serum triglyceride levels can develop because of mutations in different apolipoprotein genes such as APOAI, APOCIII, APOAIV and APOA5. 19 Among these, APOCIII and the recently identified APOA5 genes have a regulatory role in triglyceride metabolism. [20] [21] [22] APOA5 influences the triglyceride metabolism by 2 possible mechanisms: (1) enhancing intravascular triglyceride hydrolysis by activating the lipoprotein lipase, and (2) decreasing the serum concentration of triglycerides through inhibition of hepatic very-low-density lipoprotein-triglyceride production. 23, 24 Polymorphisms of APOA5 can influence the function of the protein transcript, which can modify secondarily the interaction of APOA5 with the lipoprotein lipase and result ultimately in increased circulating triglyceride levels. [25] [26] [27] The most frequently examined naturally occurring polymorphisms of APOA5 are the T-1131C, T1259C, C56G, and IVS3+G476A allelic variants. These variants have been investigated in relation to their possible modifying effect on lipid metabolism and in relation to their possible impact on the development of cardio-and cerebrovascular diseases. 11, 12, 28, 29 In the present study the possible relationships between the presence of the 1259C and IVS3+476A alleles and the development of ischemic stroke were examined in a stratified stroke population, for the first time in the literature. Besides this, the study design enabled us to also investigate the allele distribution of the T-1131C variants, which had been found to confer risk for the disease in our previous study. 14 We found that carrying the minor alleles of all 3 APOA5 variants was associated with increased triglyceride levels in both the stroke patients and the controls. Our finding is in agreement with those of others using different study populations; bearing these allelic variants has been shown to have obligatory associations with increased triglyceride levels, independent of geographic origin or disease of the population examined. [29] [30] [31] [32] We also compared the serum cholesterol levels in all groups, but we could not detect an association between carrying any allele and cholesterol level, which is consistent with the observations of others; 11, 33 however, in some studies, changes in cholesterol levels were observed in carriers of the -1131C allele. 34, 35 In the present stroke patients, there was an approximately 2-fold accumulation in the -1131C as well as in the IVS3+ 476A alleles, whereas the distribution of the 1259C allele was almost the same in patients with stroke and in controls. Table 2 .
Using multivariate logistic regression analyses we found strong associations between the IVS3+476A allelic variant and the development of stroke, but not between the presence of the 1259C allele and susceptibility for the disease. Thus, our observations suggest that bearing the 1259C allele does not confer independent risk for this cerebrovascular disease. That result seems to be strengthened by other studies: the T1259C and IVS3+476A variants were found to elevate triglyceride levels, but the 1259C allele was not found to confer risk for myocardial infarction or carotid stenosis. 11, 29 By contrast, evidence for a role of IVS3+476A allelic variant has been presented in cases of variation in the intimamedia thickness of the common carotid artery 11 and in the development of metabolic syndrome. 36 Intimal thickness is known to have a direct role in the development of arterial obstruction and ultimately of stroke. The analyses of the 3 naturally occurring APOA5 variants enabled us to partially investigate the distribution and susceptibility of -1131C, 1259C and IVS3+476A in determining the APOA5*2 haplotype. The statistical analyses revealed that the prevalence of APOA5*2 was significantly higher in all stroke subgroups than in controls and that this haplotype confers risk for the development of ischemic stroke, nevertheless, among the examined alterations only T-1131C and IVS3+G476A conferred susceptibility for stroke. However, for a more extended haplotype analysis, the distribution of the most frequently examined APOA5 variants (T-1131C, T1259C, IVS3+G476A, C56G) should be analyzed in a larger population of stroke patients.
